More deaths, no benefit from malaria drug in VA virus study
Well, that was an interesting larger study of hydroxycloroquine, but unfortunately it seemed to do more harm than good.
A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers reported.
The nationwide study was not a rigorous experiment. But with 368 patients, it’s the largest look so far of hydroxychloroquine with or without the antibiotic azithromycin for COVID-19, which has killed more than 171,000 people as of Tuesday.
Well, that was an interesting larger study of hydroxycloroquine, but unfortunately it seemed to do more harm than good.